Joshua Montroy
Overview
Explore the profile of Joshua Montroy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis P, Montroy J, Warshawsky B, Abrams E, Coward L, Killikelly A
Vaccine
. 2025 Mar;
53:126878.
PMID: 40081151
Introduction: Human rabies is rare, though almost universally fatal. Rabies pre-exposure prophylaxis (PrEP) simplifies the post-exposure prophylaxis regimen and may offer some protection from unrecognized rabies exposures. Several different PrEP...
2.
Montroy J, Yan C, Khan F, Forbes N, Krishnan R, Tunis M, et al.
Vaccine
. 2025 Jan;
47:126706.
PMID: 39787800
Background: In susceptible individuals, post-exposure prophylaxis (PEP) is often recommended following exposure to measles, however the data that these recommendations are based on are limited. The objective of this systematic...
3.
Lim S, Hersi M, Krishnan R, Montroy J, Rook B, Farrah K, et al.
Vaccine X
. 2024 Nov;
21:100575.
PMID: 39555243
Background: The COVID-19 pandemic resulted in a rapid accumulation of novel vaccine research evidence. As a means to monitor this evidence, the Public Health Agency of Canada (PHAC) created the...
4.
Montroy J, Salvadori M, Forbes N, Dubey V, Almasri S, Jirovec A, et al.
Can Commun Dis Rep
. 2024 Jul;
50(6):166-178.
PMID: 39021378
Background: Current National Advisory Committee on Immunization (NACI) guidance recommends human papillomavirus (HPV) vaccines be administered as a two or three-dose schedule. Recently, several large clinical trials have reported the...
5.
Sobh M, Lagali P, Ghiasi M, Montroy J, Dollin M, Hurley B, et al.
Transl Vis Sci Technol
. 2023 Nov;
12(11):24.
PMID: 37982768
Purpose: This systematic review evaluates the safety and efficacy of ocular gene therapy using adeno-associated virus (AAV). Methods: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched...
6.
Hunniford V, Grudniewicz A, Fergusson D, Montroy J, Grigor E, Lansdell C, et al.
Elife
. 2023 Mar;
12.
PMID: 36892457
Background: Multicentric approaches are widely used in clinical trials to assess the generalizability of findings, however, they are novel in laboratory-based experimentation. It is unclear how multilaboratory studies may differ...
7.
Bastin D, Montroy J, Kennedy M, Martel A, Shorr R, Ghiasi M, et al.
Sci Rep
. 2023 Feb;
13(1):3347.
PMID: 36849805
We conducted a systematic review and meta-analysis of randomized control trials to formally assess the safety and efficacy of autologous whole cell vaccines as immunotherapies for solid tumors. Our primary...
8.
Lalu M, Kekre N, Montroy J, Ghiasi M, Hay K, McComb S, et al.
Syst Rev
. 2023 Jan;
12(1):9.
PMID: 36653879
Background: Chimeric antigen receptor T cell therapy (CAR-T) represents a promising and exciting new therapy for hematologic malignancies, where prognosis for relapsed/refractory patients remains poor. Encouraging results from clinical trials...
9.
Lalu M, Presseau J, Foster M, Hunniford V, Cobey K, Brehaut J, et al.
PLoS Biol
. 2023 Jan;
21(1):e3001932.
PMID: 36603053
Use of rigorous study design methods and transparent reporting in publications are 2 key strategies proposed to improve the reproducibility of preclinical research. Despite promotion of these practices by funders...
10.
Fox G, Fergusson D, Foster M, Hawrysh T, Dupont S, Walling D, et al.
Healthc Q
. 2022 Apr;
24(SP):74-79.
PMID: 35467515
Engaging patients as partners in the design and execution of early-phase clinical trials offers a unique opportunity to ensure patient perspectives are considered. Here we describe our experience partnering with...